Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

132 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. Poser CM, et al. Among authors: silberberg dh. Ann Neurol. 1983 Mar;13(3):227-31. doi: 10.1002/ana.410130302. Ann Neurol. 1983. PMID: 6847134 No abstract available.
Clinical trials in multiple sclerosis. Problems and opportunities.
Silberberg DH. Silberberg DH. Ann N Y Acad Sci. 1984;436:418-24. doi: 10.1111/j.1749-6632.1984.tb14813.x. Ann N Y Acad Sci. 1984. PMID: 6398022 Clinical Trial. No abstract available.
Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging.
Gonzalez-Scarano F, Grossman RI, Galetta S, Atlas SW, Silberberg DH. Gonzalez-Scarano F, et al. Among authors: silberberg dh. Ann Neurol. 1987 Mar;21(3):300-6. doi: 10.1002/ana.410210312. Ann Neurol. 1987. PMID: 3606036
Revised estimate of the prevalence of multiple sclerosis in the United States.
Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Anderson DW, et al. Among authors: silberberg dh. Ann Neurol. 1992 Mar;31(3):333-6. doi: 10.1002/ana.410310317. Ann Neurol. 1992. PMID: 1637140
Azathioprine in multiple sclerosis: the cons.
Silberberg DH. Silberberg DH. Neurology. 1988 Jul;38(7 Suppl 2):24-7. Neurology. 1988. PMID: 3290710 Clinical Trial.
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Goodin DS, et al. Among authors: silberberg dh. Neurology. 2002 Jan 22;58(2):169-78. doi: 10.1212/wnl.58.2.169. Neurology. 2002. PMID: 11805241 No abstract available.
Optic nerve demyelination induced by human serum: patients with multiple sclerosis or optic neuritis and normal subjects.
Sergott RC, Brown MJ, Polenta RM, Lisak RP, Silberberg DH. Sergott RC, et al. Among authors: silberberg dh. Neurology. 1985 Oct;35(10):1438-42. doi: 10.1212/wnl.35.10.1438. Neurology. 1985. PMID: 4033926
Serum-mediated oligodendrocyte cytotoxicity in multiple sclerosis patients and controls.
Hirayama M, Lisak RP, Silberberg DH. Hirayama M, et al. Among authors: silberberg dh. Neurology. 1986 Feb;36(2):276-8. doi: 10.1212/wnl.36.2.276. Neurology. 1986. PMID: 3945400
The design of clinical studies to assess therapeutic efficacy in multiple sclerosis.
Brown JR, Beebe GW, Kurtzke JF, Loewenson RB, Silberberg DH, Tourtellotte WW. Brown JR, et al. Among authors: silberberg dh. Neurology. 1979 Sep;29(9 pt. 2):3-23. doi: 10.1212/wnl.29.9_part_2.3. Neurology. 1979. PMID: 381971 Review.
Multiple sclerosis unaffected by azathioprine in pilot study.
Silberberg D, Lisak R, Zweiman B. Silberberg D, et al. Arch Neurol. 1973 Mar;28(3):210-2. doi: 10.1001/archneur.1973.00490210090017. Arch Neurol. 1973. PMID: 4119511 No abstract available.
132 results
Jump to page
Feedback